Back to Stocks

ICUI

ICU MEDICAL INC/DE
7 filings tracked
healthcaremedical devicesMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

ICU Medical is successfully executing a structural transformation, shifting from a capital-intensive, low-margin IV fluids business toward a high-margin, innovation-led infusion therapy platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a strategic pivot, ICU Medical's core business shows signs of fragility, with total revenues falling 12% year-over-year to $530 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ICUI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing depicts a company in the midst of a high-stakes identity shift. By shedding the low-margin IV fluids business, ICU Medical has successfully engineered a rapid improvement in gross margins and a return to profitability, reporting net income of $30.1 million compared to a loss in the prior year. However, this financial recovery is partially skewed by a $29.2 million one-time tax benefit and the immediate impact of a major asset sale, masking the underlying decline in total top-line revenue. Investors are now weighing the benefit of a cleaner, higher-margin business model against the risks of extreme product concentration and lingering regulatory uncertainty. While the debt reduction and new product clearances provide a bullish foundation, the unresolved FDA issues and the pressure of a $1.26 billion debt load create a volatile risk profile. The ultimate success of the turnaround depends on whether the Plum precision pump platform can scale fast enough to offset the loss of the IV Solutions revenue and satisfy the company's heavy financial obligations.

Selected Quarter

Core Takeaway

ICU Medical has successfully improved its profit profile and reduced debt, but now faces higher concentration risk and unresolved regulatory hurdles.

Investor Lens

The trade-off is between an improved margin profile and a significantly narrowed revenue base with higher regulatory sensitivity.

Watch Next

FDA clearance status for the next-generation MedFusion and CADD infusion pumps.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.26Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion
90%
bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat
70%
neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture
60%
bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure
50%
bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action
80%
bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion
90%
bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat
70%
neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture
60%
bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure
50%
bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action
80%
bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion
90%
bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat
70%
neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture
60%
bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure
50%
bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action
80%
bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion
90%
bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat
70%
neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture
60%
bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure
50%
bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action
80%
bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion
90%
bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat
70%
neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture
60%
bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure
50%
bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action
80%
bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion
90%
bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat
70%
neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture
60%
bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure
50%
bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action
80%
bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion
90%
bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat
70%
neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture
60%
bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure
50%
bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action
80%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing depicts a company in the midst of a high-stakes identity shift. By shedding the low-margin IV fluids business, ICU Medical has successfully engineered a rapid improvement in gross margins and a return to profitability, reporting net income of $30.1 million compared to a loss in the prior year. However, this financial recovery is partially skewed by a $29.2 million one-time tax benefit and the immediate impact of a major asset sale, masking the underlying decline in total top-line revenue. Investors are now weighing the benefit of a cleaner, higher-margin business model against the risks of extreme product concentration and lingering regulatory uncertainty. While the debt reduction and new product clearances provide a bullish foundation, the unresolved FDA issues and the pressure of a $1.26 billion debt load create a volatile risk profile. The ultimate success of the turnaround depends on whether the Plum precision pump platform can scale fast enough to offset the loss of the IV Solutions revenue and satisfy the company's heavy financial obligations.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.